Introduction
Mixed states present particular challenges to the treating clinician and even the prevalence rate changes significantly among studies and in relation to diagnostic criteria used. In DSM-IV, a diagnosis of a mixed episode required simultaneously all criteria for a manic or a major depressive episode. In clinical practice individuals infrequently meet these full criteria. After a 14-year development process including approximately 400 people from different professions and 39 countries, DSM-5 appeared in May 2013. The new DSM-5 ''specifier'' adopts a broader approach towards mixed states. In the case of depressive episodes, there is a requirement for the presence of at least three manic/hypomanic symptoms (including elevated mood, inflated self-esteem, decreased need for sleep and an increase in energy or goal-directed activities), occurring nearly every day during the most recent two weeks of the major depressive episode, notably overlap with symptoms of major depression is restricted. In the case of mania or hypomania, the specifier requires the presence of at least three symptoms of depression (including depressed mood, diminished interest or pleasure, slowed physical and emotional reaction, fatigue or loss of energy, and recurrent thoughts of death) together with the episode of mania/hypomania, nearly every day throughout the most recent week of a manic episode or during the most recent four days of a hypomanic episode.
Mixed states are generally held to be less responsive to pharmacological treatment and response to mood stabilizers and other pharmacotherapies is poor 1, 2 . Antidepressants are generally avoided because of exacerbation of manic symptoms and a feared increased risk of suicidality which is already high 3 . However, the use of an atypical antipsychotic-antimanic agent in some bipolar disorder patients may decrease suicidal ideation 4 . As a result, the choice of medication is usually based on individual factors and short/long-term harms, safety and tolerability parameters. The aim of this review is to review the pharmacological treatment of ''mixed states/episodes'' as defined by DSM-IV and DSM-5 manic episodes ''with mixed features'' . the reference lists of every identified primary study.
Methods

Searches
Study selection
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 5 guidelines. Articles were screened and selected for full-text review if they met our selection criteria. Once identified titles and abstracts were reviewed independently by two the authors (AC,, AY) and discrepancies were resolved by consensus among all the authors.
Quality assessment
First-degree studies included double blind, placebo controlled randomised controlled trials (RCTs) of pharmacological interventions used in monotherapy. Second-degree referred to a similar design without placebo group +/-combination therapy and third degree referred to any other type of published studies.
Results
The searches identified 913 studies of which 73 met inclusion criteria and investigated mixed states in bipolar disorder. Non-original studies (including editorials, book reviews and letters to the editor) and studies without full-text available were excluded.
These studies evaluated antipsychotics (n=39), mood stabilizers (n=14) and combination therapies 
Antipsychotic medication with mood stabilising properties
1) OLANZAPINE
Acute treatment studies (≤ 8 weeks)
We identified two first degree studies comparing olanzapine with placebo 6, 7 , one second degree evidence study comparing olanzapine with haloperidol 8 and two with risperidone 9, 10 .
Longer term (≥ 8 weeks), maintenance and relapse prevention studies treated with a combination therapy of these two compounds (for 6-12 weeks).
2) QUETIAPINE Acute treatment (≤ 8 weeks)
We identified five first degree acute phase studies. Three studies compared quetiapine with placebo [15] [16] [17] and two compared quetiapine with lithium or paroxetine and placebo 18, 19 . Another randomized controlled study compared quetiapine with paliperidone extended release to placebo (see paliperidone). A second degree evidence continuation phase of the study which compared quetiapine with paliperidone without placebo is descibed below (see paliperidone) 20 .
Longer term (≥ 8 weeks), maintenance and relapse prevention studies
One maintenance study compared quetiapine with lithium and placebo as open label extension of a randomised controlled trial in Bipolar I disorder for up to 104 weeks 21 ..
3) ARIPIPRAZOLE Acute treatment (≤ 8 weeks)
We identified five first degree evidence acute phase trials with aripiprazole. Four studies compared aripiprazole with placebo 22-25 and one with lithium and placebo 26 . A one second degree evidence comparison trial analyzed the efficacy of aripiprazole vs. haloperidol 27 . Review Article
Longer term (≥ 8 weeks), maintenance and relapse prevention studies
We identified one first degree long term trial which compared aripiprazole with placebo 28 and two second degree extension studies 26,27 comparing aripiprazole with lithium and haloperidol respectively (the treatment received in the first 3 week of treatment are discussed above).
4) ASENAPINE Acute treatment (≤ 8 weeks)
There are two first degree evidence trials 29,30 assessing asenapine in the managment of mixed affective symptoms compared with olanzapine and placebo. McIntyre and others combined the above described studies 29,30 in a post-hoc analysis 31 based on the DSM-5 mixed specifier for the diagnosis of manic episodes.
Longer term (≥ 8 weeks), maintenance and relapse prevention studies
We reported two second degree evidence trials regarding long term treatment of asenapine compared with olanzapine by McIntyre and others. The authors designed these two stepped progressive studies originating from the first 3 week trial by randomising the placebo group into active treatment 32,33 .
5) LURASIDONE Acute treatment (≤ 8 weeks)
We found evidence of efficacy in acute bipolar depression, supported by two monotherapy randomized clinical trials 34, 35 and one second degree adjunctive therapy study (see combination therapy) 36 . Review Article
Longer term (≥ 8 weeks), maintenance and relapse prevention studies
No studies were identified.
6) ZIPRASIDONE Acute treatment (≤ 8-weeks)
We identified one first degree evidence trial assessing efficacy of ziprasidone compared with placebo in major depressive episodes with 2 or 3 concomitant manic symptoms 37 . A second degree study is available from a pooled analysis 38 of mixed patient with dysphoric mania previously enrolled in two similar placebo controlled trials 39, 40 .
Longer term (≥ 8 weeks), maintenance and relapse prevention studies
7) RISPERIDONE Acute treatment (≤ 8-weeks)
We identifyed one firts degree trial 41 comparing risperidone to placebo in mixed affective conditions.
Longer term (≥ 8 weeks), maintenance and relapse prevention studies
No studies were available.
8) PALIPERIDONE Review Article
Acute treatment (≤8-weeks)
We indentified two first degree trials 20,42 assessing efficacy of paliperidone in mixed affective conditions.
Longer term (≥ 8 weeks), maintenance and relapse prevention studies
Vieta et al. performed a randomized, placebo-active-controlled study of paliperidone extended release for the treatment of acute manic and mixed Bipolar I disorder 20 ..
9) CLOZAPINE Acute and maintenance treatment
In a case series by Suppes and others 85 consecutive patients were treated with clozapine. Seven subjects had treatment-resistant bipolar disorder and manic episodes associated with significant depressive symptoms. All patients displayed significant reductions in affective and psychotic symptoms when treated with clozapine alone or in combination with lithium, an antidepressant, or sodium valproate. Clozapine effects were often evident within the first few weeks of treatment and sustained over the 3-5 years follow-up period 43 .
10) CARIPRAZINE Acute treatment (≤ 8-weeks)
The three identified first degree randomized controlled trials measured the effect of cariprazine on manic and depressive symptoms in acute mania or mixed episodes [44] [45] [46] .
Longer term (≥ 8 weeks), maintenance and relapse prevention studies Review Article
Longer-term treatment of subjects with Bipolar I illness was investigated in an open, 16-week study that followed up 402 patients 47, 48 .
Ongoing trials
An ongoing international 8-week study 49 of cariprazine vs. placebo in bipolar depression registrated on the ClinicalTrials.gov website is currently investigating subjects with Bipolar I depression with a verified previous manic or mixed episode, without psychotic features, aged 18-65 , total HAMD score of ≥20, HAMD Item 1 score of ≥2, and CGI-S of ≥4 to be randomized to cariprazine 0.75, 1.5, or 3.0 mg/day, or placebo.
Mood stabilizers in managment of mixed affective features
1) DIVALPROEX Acute treatment (≤ 8 weeks)
We found four first degree Divalproex vs. placebo acute treatment trials [50] [51] [52] [53] .
Maintenance treatment (≥ 8 weeks)
No maintenance or relapse prevention trials with divalproex monotherapy were found. Comparison studies are analized in the section below (see lithium).
2) LITHIUM Acute treatment (≤ 16 weeks)
We identifyed two second degree comparison trials with divalproex (in manic/mixed bipolar patients) 54 or lamotrigine 55 in bipolar depression.
Maintenance/relapse prevention treatment (≥ 16 weeks)
Only one trial was identified comparing lithium monotherapy vs. placebo as a prophylactic intervention in major unipolar depression and hypomania in bipolar disorder 56 . Three long-term phase trials compared lithium with divalproex and placebo 57 and two lithium with lamotrigine and placebo (described with lamotrigine below).
3) CARBAMAZEPINE Acute treatment (≤ 8 weeks)
Weisler and others 58 reported a post hoc analysis of two randomised controlled studies 59, 60 . The first trial showed higher response rates in mixed or manic patients treated with carbamazepine-extended release (CBZ-ER) vs. placebo (42% vs. 22% rispectively). The second trial reported response rates in acute manic patient treated with CBZ-ER vs. placebo in the range of 60.8% and 28.7%
respectively for mixed patients suggesting that carbamazepine might be effective to treat both manic and depressive symptoms.
Maintenance treatment (≥ 8 weeks)
Ketter and colleagues 61 , in an additional secondary analysis confirmed that also long-term monotherapy with extended-release is efficacious against Bipolar I disorder mixed and manic episodes.
4) LAMOTRIGINE Acute treatment (≤ 16 week)
We found only one first degree study of Bipolar I disorder experiencing a major depressive episode treated with lamotrigine (50 or 200 mg/day) or placebo in monotherapy for a 7-week period.
62
Maintenance/ relapse prevention (≥ 16 weeks)
Two first degree trials compared lamotrigine with lithium 63,64 .
5) GABAPENTIN Review Article
Only one open label study investigated gabapentin as adjunctive treatment for treatment resistant Bipolar mixed states presenting at both poles of the illness 65 .
COMBINATION THERAPY
1) ARIPIPRAZOLE PLUS MOOD STABIZERS Acute treatment (≥ 8 weeks)
One trial investigated aripiprazole adjuvant to other mood stabilizers (lithium or valproate) in the treatment of acute phase mixed states 66 .
Longer term maintenance or relapse prevention (≥ 8 weeks)
Two first degree trials 67,68 compared aripiprazole adjunct to a stabilizers (lithium/valproate and lamotrigine) vs. placebo. A further second degree extension trial compared aripiprazole with lthium or valproate without the placebo arm 69 .
2) OLANZPINE PLUS MOOD STABILIZERS Acute treatment (≤ 8 weeks)
Three first degree trials compared olanazapine with a mood stabilizer (lithium or valproate) vs. placebo [70] [71] [72] .
Longer term maintenance/relapse prevention (≥ 8 weeks)
Tohen et al. followed up patients who achieved syndromic remission for 18 months in a doubleblind trial 73 , derived from the 6 weeks trial discussed above 71 .
3) OLANZPINE -FLUOXETINE COMBINATION (OFC) Acute treatment (≤ 8 weeks)
One first degree study 74 compared olanzapine monotherapy and in combination (OFC) vs. placebo which included a post-hoc mixed depressed patients analysis. Two second degree trials were also available assessing OFC vs. lamotrigine in bipolar depression with fixed 75 and flexible doses 76 .
Longer term maintenance and relapse prevention (≥ 8 weeks)
Brown and others also conducted a 6-month long-term follow-up trial 77 of the 7-week study above 76 and reported greater response of OFC flexible doses in comparison with lamotrigine (titrated up to 200 mg/day) for both depressive and manic symptoms in Bipolar depression.
4) QUETIAPINE PLUS MOOD STABILIZERS Acute treatment (≤ 8 weeks)
Suppes and others assessed adjunctive quetiapine treatment in Bipolar II patients experiencing hypomania with mixed symptoms in a two-site, randomized, placebo-controlled, double-blind, 8-week investigation 78 .
Longer term maintenance/relapse prevention (≥ 8 weeks)
Two placebo-controlled trials 79, 80 evaluated maintenance treatment with quetiapine (compared to placebo) as an adjunct to lithium or divalproex.
5) RISPERIDONE PLUS MOOD STABILIZERS Acute treatment (≤ 8 weeks)
No studies were found.
Longer term manitenzance/relapse prevention (≥ 8 weeks)
24-week, open-label third-degree combination trial 81 .
6) LURASIDONE PLUS MOOD STABILIZERS Acute treatment (≤ 8 weeks)
Loebel and others investigated the efficacy of lurasidone as adjunctive therapy with lithium or valproate for the treatment of Bipolar I depression in a 6-week, randomized, placebo-controlled trial 36 .
Longer term maintenance/relapse prevention
No trials available for review.
7) ZIPRASIDONE PLUS MOOD STABILIZERS Acute treatment (≤ 8 weeks)
Longer term maintenance/relapse prevention (≥ 8 weeks)
Bowden and colleagues assessed the maintenance efficacy of ziprasidone compared to placebo as an adjunct to a mood stabilizer in manic/mixed bipolar I patients for up to 6 months (after ≥ 8 consecutive weeks of stability with open-label ziprasidone and lithium or valproate) 82 .
8) LAMOTRIGINE PLUS MOOD STABILIZERS
Acute treatment (≤ 8 weeks)
Van der Loos and colleagues 83 added lamotrigine or placebo to the ongoing lithium treatment of patients with bipolar depression.
Longer term maintenance/relapse prevention (≥ 8 weeks)
Bowden and others trialled lamotrigine alone or in combination with divalproex-extended release in recently depressed patients with bipolar disorder in a maintenance study after 8-week open stabilization phase with lamotrigine or divalproex 84 .
Discussion
We found that the vast majority of published RCTs initially recruited both pure manic and mixed patients as defined in the DSM-IV classification system and that additional sub-analyses were performed to identify effects in a subgroup of mixed patients. A major shortfall in the literature is that mixed depressive cases are not usually reported in depression RCTs. This subgroup approach has several shortcomings: first, the resulting sample sizes are usually small and thus "negative" References, tables and figures.
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